Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409142 | 0.93 | RBP4 (0.60) | RBP4KDM4EMAPK1GAAALDH1A1 | |
| SCHEMBL1901487 | 0.91 | RBP4 (0.61) | RBP4KDM4EMAPK1GAAALDH1A1 | |
| SCHEMBL12409225 | 0.89 | RBP4 (0.61) | RBP4KDM4EMAPK1GAAALDH1A1 | |
| SCHEMBL1898327 | 0.84 | RBP4 (0.64) | RBP4KDM4EMAPK1GAAALDH1A1 | |
| SCHEMBL12409190 | 0.83 | RBP4 (0.52) | RBP4KDM4EMAPK1GAAALDH1A1 | |
| SCHEMBL12409171 | 0.83 | RBP4 (0.50) | RBP4KDM4EMAPK1GAAALDH1A1 | |
| SCHEMBL12409183 | 0.82 | RBP4 (0.52) | RBP4KDM4EMAPK1GAAALDH1A1 | |
| SCHEMBL12409179 | 0.82 | RBP4 (0.49) | RBP4KDM4EMAPK1GAAALDH1A1 | |
| SCHEMBL12489893 | 0.82 | RBP4 (0.62) | RBP4KDM4EMAPK1GAAALDH1A1 | |
| SCHEMBL12409182 | 0.82 | RBP4 (0.51) | RBP4KDM4EMAPK1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012591-A1 | PROPHYLAXIS OF SKIN CANCER WITH RETINAMIDES | REVISION THERAPEUTICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012591-A1 | PROPHYLAXIS OF SKIN CANCER WITH RETINAMIDES | ALDH1A2, ALDH1A3, CRABP2 | RBP4 5/4885KDM4E 462/4885MAPK1 4451/4885 |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, ALDH1A2 | RBP4 2/4885KDM4E 4096/4885MAPK1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.